1. Generics Bulletin
  2. >>Business

Sandoz Victoza Settlement Sets Up Face-Off With Teva And Viatris

Novo Nordisk: Sandoz Able To Launch Liraglutide In June 2024

 
• By Dean Rudge

Novo Nordisk’s cornerstone type 2 diabetes treatment Victoza is set to come under siege from the three largest generics manufacturers beginning in June 2024, after Sandoz became the last of the trio to sign a licensing agreement with the Danish originator that resolves patent-litigation proceedings.

Three Targets Arrows
The big three all have their sights on Gx Victoza • Source: le Moal Olivier / Alamy Stock Photo

Teva, Viatris and Sandoz are set to face off with generic versions of Novo Nordisk’s GLP-1 analog Victoza (liraglutide) injectable in the US at the same time after the Novartis business became the latest company to resolve patent-litigation proceedings with the Danish originator.

Court documents filed with a district court in Delaware disclose that Novo Nordisk and Sandoz have agreed to terms and conditions “representing a negotiated settlement of this action,” with those terms and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.